Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion

•Majority of ALK-positive patients (53.6%) were PD-L1 expression TPS 

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2023-07, Vol.181, p.107233-107233, Article 107233
Main Authors: Pan, Yingying, Liu, Xinyu, Zhang, Wei, Wang, Wanying, Wang, Haowei, Luo, Libo, Jia, Keyi, Shao, Chuchu, Mao, Shiqi, Qiu, Tianyu, Ni, Jun, Yu, Jia, Wang, Lei, Chen, Bin, Xiong, Anwen, Gao, Guanghui, Chen, Xiaoxia, Wu, Fengying, Zhou, Caicun, Wu, Chunyan, Ren, Shengxiang
Format: Article
Language:English
Subjects:
Alectinib
ALK fusion
Anaplastic Lymphoma Kinase
B7-H1 Antigen - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
China
ErbB Receptors
Humans
Lung cancer
Lung Neoplasms - pathology
PD-L1 expression
Protein Kinase Inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Majority of ALK-positive patients (53.6%) were PD-L1 expression TPS 
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2023.107233